| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gold | 16 | 2023 | 267 | 3.860 |
Why?
|
| Metal Nanoparticles | 8 | 2024 | 161 | 3.440 |
Why?
|
| Nanoparticles | 13 | 2024 | 585 | 3.070 |
Why?
|
| Arteriovenous Fistula | 5 | 2024 | 101 | 2.860 |
Why?
|
| Vena Cava Filters | 6 | 2023 | 90 | 2.750 |
Why?
|
| Bismuth | 4 | 2024 | 102 | 2.230 |
Why?
|
| Nanoshells | 5 | 2014 | 43 | 2.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2024 | 205 | 1.790 |
Why?
|
| Nanomedicine | 4 | 2022 | 53 | 1.770 |
Why?
|
| Magnetite Nanoparticles | 3 | 2018 | 53 | 1.660 |
Why?
|
| Polymers | 5 | 2024 | 222 | 1.660 |
Why?
|
| Neointima | 4 | 2024 | 58 | 1.570 |
Why?
|
| Drug Delivery Systems | 7 | 2022 | 661 | 1.530 |
Why?
|
| Polyglutamic Acid | 5 | 2011 | 49 | 1.410 |
Why?
|
| Polyesters | 3 | 2024 | 68 | 1.400 |
Why?
|
| Hyperplasia | 3 | 2024 | 564 | 1.220 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2024 | 2156 | 1.210 |
Why?
|
| Electroporation | 5 | 2021 | 127 | 1.200 |
Why?
|
| Iodine | 2 | 2020 | 55 | 1.190 |
Why?
|
| Nanostructures | 3 | 2024 | 100 | 1.180 |
Why?
|
| Drug Carriers | 7 | 2021 | 336 | 1.160 |
Why?
|
| Contrast Media | 7 | 2024 | 1499 | 1.100 |
Why?
|
| Mice, Nude | 16 | 2023 | 4329 | 1.060 |
Why?
|
| Tissue Scaffolds | 2 | 2024 | 134 | 1.060 |
Why?
|
| Bone Neoplasms | 5 | 2024 | 2665 | 1.060 |
Why?
|
| Nanospheres | 4 | 2014 | 35 | 1.040 |
Why?
|
| Quinolines | 2 | 2019 | 402 | 1.020 |
Why?
|
| Phantoms, Imaging | 3 | 2024 | 1330 | 0.980 |
Why?
|
| Rosuvastatin Calcium | 1 | 2024 | 49 | 0.940 |
Why?
|
| Animals | 47 | 2024 | 61956 | 0.880 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2019 | 7895 | 0.850 |
Why?
|
| Imidazoles | 2 | 2019 | 1065 | 0.850 |
Why?
|
| Radium | 2 | 2021 | 97 | 0.840 |
Why?
|
| Prostatic Neoplasms | 6 | 2024 | 5866 | 0.820 |
Why?
|
| Hepatic Artery | 2 | 2021 | 255 | 0.820 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 14617 | 0.810 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2023 | 106 | 0.810 |
Why?
|
| Ethiodized Oil | 1 | 2021 | 17 | 0.800 |
Why?
|
| Liposomes | 3 | 2019 | 704 | 0.790 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2021 | 73 | 0.770 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 342 | 0.770 |
Why?
|
| Rats | 10 | 2024 | 6441 | 0.740 |
Why?
|
| Photoacoustic Techniques | 2 | 2018 | 55 | 0.690 |
Why?
|
| Sirolimus | 1 | 2024 | 831 | 0.680 |
Why?
|
| Portal Vein | 1 | 2021 | 363 | 0.660 |
Why?
|
| Laser Therapy | 3 | 2013 | 466 | 0.650 |
Why?
|
| Cell Line, Tumor | 20 | 2024 | 14849 | 0.620 |
Why?
|
| Infrared Rays | 5 | 2016 | 62 | 0.610 |
Why?
|
| Nanotechnology | 4 | 2022 | 137 | 0.600 |
Why?
|
| Nanopores | 1 | 2017 | 16 | 0.590 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2024 | 7783 | 0.590 |
Why?
|
| Swine | 6 | 2023 | 1607 | 0.580 |
Why?
|
| Absorbable Implants | 3 | 2023 | 60 | 0.580 |
Why?
|
| Neoplasms | 11 | 2015 | 15927 | 0.570 |
Why?
|
| Hyperthermia, Induced | 4 | 2016 | 511 | 0.560 |
Why?
|
| Light | 2 | 2014 | 279 | 0.530 |
Why?
|
| ErbB Receptors | 4 | 2014 | 2375 | 0.520 |
Why?
|
| Head and Neck Neoplasms | 3 | 2019 | 4147 | 0.520 |
Why?
|
| Mice | 25 | 2024 | 35600 | 0.510 |
Why?
|
| Renal Dialysis | 1 | 2022 | 917 | 0.500 |
Why?
|
| Dioxanes | 1 | 2015 | 11 | 0.500 |
Why?
|
| Dextrans | 1 | 2015 | 98 | 0.500 |
Why?
|
| Liver Neoplasms | 5 | 2021 | 4821 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 751 | 0.490 |
Why?
|
| Macrophages | 3 | 2024 | 1350 | 0.470 |
Why?
|
| Indoles | 3 | 2017 | 1028 | 0.460 |
Why?
|
| Technology, Pharmaceutical | 1 | 2014 | 28 | 0.460 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2017 | 742 | 0.450 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 202 | 0.450 |
Why?
|
| Tensile Strength | 3 | 2020 | 76 | 0.450 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 968 | 0.440 |
Why?
|
| Doxorubicin | 4 | 2017 | 3145 | 0.430 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2011 | 172 | 0.420 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2015 | 186 | 0.410 |
Why?
|
| Liver | 2 | 2021 | 3086 | 0.410 |
Why?
|
| Cell Survival | 4 | 2019 | 3063 | 0.370 |
Why?
|
| Antibodies | 1 | 2014 | 809 | 0.370 |
Why?
|
| Capillary Permeability | 1 | 2011 | 116 | 0.370 |
Why?
|
| Solubility | 3 | 2019 | 247 | 0.360 |
Why?
|
| Glioma | 3 | 2018 | 1978 | 0.360 |
Why?
|
| Hot Temperature | 1 | 2011 | 289 | 0.350 |
Why?
|
| Gadolinium | 1 | 2010 | 169 | 0.330 |
Why?
|
| Liver Diseases | 1 | 2014 | 602 | 0.320 |
Why?
|
| Phototherapy | 2 | 2011 | 83 | 0.320 |
Why?
|
| Models, Biological | 1 | 2017 | 3194 | 0.320 |
Why?
|
| Benzamides | 3 | 2017 | 1879 | 0.310 |
Why?
|
| Vena Cava, Inferior | 3 | 2023 | 194 | 0.310 |
Why?
|
| Humans | 36 | 2024 | 270740 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 1586 | 0.310 |
Why?
|
| Fluorescent Dyes | 2 | 2007 | 467 | 0.310 |
Why?
|
| Stem Cells | 1 | 2014 | 1216 | 0.290 |
Why?
|
| Endothelial Cells | 2 | 2024 | 1038 | 0.290 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 3707 | 0.260 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 2175 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 5593 | 0.260 |
Why?
|
| X-Ray Microtomography | 2 | 2017 | 136 | 0.250 |
Why?
|
| Ytterbium | 1 | 2024 | 6 | 0.240 |
Why?
|
| Drug Liberation | 1 | 2024 | 19 | 0.240 |
Why?
|
| Low-Level Light Therapy | 2 | 2016 | 28 | 0.240 |
Why?
|
| Optical Imaging | 2 | 2017 | 158 | 0.230 |
Why?
|
| Radiopharmaceuticals | 3 | 2021 | 1341 | 0.230 |
Why?
|
| Radiology, Interventional | 2 | 2022 | 142 | 0.230 |
Why?
|
| Hydroxyapatites | 1 | 2023 | 11 | 0.220 |
Why?
|
| Alendronate | 1 | 2023 | 24 | 0.220 |
Why?
|
| Male | 16 | 2024 | 128315 | 0.220 |
Why?
|
| Tumor Microenvironment | 3 | 2024 | 3035 | 0.210 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 605 | 0.200 |
Why?
|
| Tissue Engineering | 1 | 2024 | 253 | 0.200 |
Why?
|
| Lasers | 2 | 2014 | 235 | 0.200 |
Why?
|
| Osteoblasts | 1 | 2024 | 393 | 0.200 |
Why?
|
| Emulsions | 1 | 2021 | 86 | 0.190 |
Why?
|
| Ablation Techniques | 2 | 2015 | 149 | 0.190 |
Why?
|
| Disease Models, Animal | 6 | 2019 | 7381 | 0.190 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 444 | 0.190 |
Why?
|
| Fluoroscopy | 1 | 2022 | 223 | 0.190 |
Why?
|
| Particle Size | 2 | 2018 | 188 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4958 | 0.190 |
Why?
|
| Rabbits | 3 | 2017 | 1028 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 4481 | 0.180 |
Why?
|
| Ferric Compounds | 2 | 2011 | 77 | 0.180 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2021 | 192 | 0.180 |
Why?
|
| Prodrugs | 1 | 2021 | 226 | 0.170 |
Why?
|
| Cyclotrons | 1 | 2019 | 10 | 0.170 |
Why?
|
| Electrochemotherapy | 1 | 2019 | 9 | 0.170 |
Why?
|
| Capsules | 1 | 2019 | 54 | 0.170 |
Why?
|
| Calibration | 1 | 2020 | 346 | 0.170 |
Why?
|
| Neoplasm Transplantation | 3 | 2014 | 1553 | 0.170 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 85 | 0.170 |
Why?
|
| In Vitro Techniques | 1 | 2021 | 1697 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 134 | 0.160 |
Why?
|
| Copper Radioisotopes | 3 | 2016 | 31 | 0.160 |
Why?
|
| Surface Properties | 2 | 2017 | 189 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 209 | 0.160 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 54 | 0.160 |
Why?
|
| Hemodynamics | 1 | 2022 | 949 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2019 | 163 | 0.150 |
Why?
|
| Surface Plasmon Resonance | 2 | 2016 | 98 | 0.150 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2014 | 334 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 4963 | 0.150 |
Why?
|
| Polydioxanone | 1 | 2017 | 7 | 0.150 |
Why?
|
| Hemofiltration | 1 | 2017 | 21 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 1690 | 0.140 |
Why?
|
| Tibia | 1 | 2017 | 125 | 0.140 |
Why?
|
| Positron-Emission Tomography | 3 | 2016 | 2197 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2018 | 445 | 0.140 |
Why?
|
| Sutures | 1 | 2017 | 93 | 0.140 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 382 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3077 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7238 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2007 | 1903 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3917 | 0.130 |
Why?
|
| Thermography | 1 | 2016 | 57 | 0.130 |
Why?
|
| Green Fluorescent Proteins | 1 | 2018 | 693 | 0.130 |
Why?
|
| Multimodal Imaging | 2 | 2016 | 550 | 0.120 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 1094 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 146 | 0.120 |
Why?
|
| Copper | 2 | 2016 | 165 | 0.120 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 87 | 0.110 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 1174 | 0.110 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 124 | 0.110 |
Why?
|
| Oxides | 1 | 2014 | 212 | 0.110 |
Why?
|
| Celiac Artery | 1 | 2013 | 43 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 190 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 655 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 261 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 2454 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 368 | 0.110 |
Why?
|
| Gene Expression | 1 | 2021 | 3640 | 0.100 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 654 | 0.100 |
Why?
|
| Radiography | 1 | 2017 | 1986 | 0.100 |
Why?
|
| Receptor, EphB4 | 1 | 2012 | 28 | 0.100 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2012 | 17 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2014 | 729 | 0.100 |
Why?
|
| Coordination Complexes | 1 | 2012 | 17 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 173 | 0.100 |
Why?
|
| Ligands | 1 | 2014 | 1012 | 0.100 |
Why?
|
| Molecular Imaging | 1 | 2013 | 186 | 0.100 |
Why?
|
| Indium | 1 | 2011 | 21 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4961 | 0.090 |
Why?
|
| Iron | 1 | 2014 | 380 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1655 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 909 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2016 | 575 | 0.090 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 804 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 513 | 0.090 |
Why?
|
| Temperature | 1 | 2011 | 538 | 0.090 |
Why?
|
| Female | 9 | 2019 | 148940 | 0.080 |
Why?
|
| Cetuximab | 1 | 2011 | 474 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1281 | 0.080 |
Why?
|
| Protein Binding | 2 | 2014 | 3485 | 0.080 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 784 | 0.080 |
Why?
|
| Quality of Life | 1 | 2023 | 4761 | 0.080 |
Why?
|
| Solutions | 1 | 2008 | 108 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33737 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 1828 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 1838 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 9039 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2014 | 1716 | 0.070 |
Why?
|
| Fluorescence Polarization | 1 | 2005 | 21 | 0.060 |
Why?
|
| Water | 1 | 2007 | 386 | 0.060 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2005 | 46 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2019 | 3557 | 0.060 |
Why?
|
| Tungsten | 1 | 2023 | 17 | 0.060 |
Why?
|
| Proteins | 1 | 2012 | 2043 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4116 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2399 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2005 | 450 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10400 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 5257 | 0.050 |
Why?
|
| Device Removal | 1 | 2023 | 339 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2007 | 3584 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 4795 | 0.040 |
Why?
|
| Gallium Isotopes | 1 | 2019 | 7 | 0.040 |
Why?
|
| Rats, Inbred BUF | 1 | 2019 | 26 | 0.040 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 62 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 3409 | 0.040 |
Why?
|
| Algorithms | 1 | 2011 | 3891 | 0.040 |
Why?
|
| Alarmins | 1 | 2019 | 8 | 0.040 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 466 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 154 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 255 | 0.040 |
Why?
|
| Quantum Dots | 1 | 2017 | 29 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2017 | 71 | 0.040 |
Why?
|
| Ferrosoferric Oxide | 1 | 2017 | 39 | 0.040 |
Why?
|
| Equipment Failure Analysis | 1 | 2017 | 322 | 0.030 |
Why?
|
| Autoradiography | 1 | 2016 | 154 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 1063 | 0.030 |
Why?
|
| Syk Kinase | 1 | 2015 | 65 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 247 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 1723 | 0.030 |
Why?
|
| Equipment Design | 1 | 2017 | 1197 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2013 | 77 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2019 | 1110 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2012 | 69 | 0.030 |
Why?
|
| Indium Radioisotopes | 1 | 2012 | 63 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1097 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1402 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1089 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 16215 | 0.020 |
Why?
|
| Citrates | 1 | 2010 | 32 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 927 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 286 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5149 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 1207 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 7100 | 0.020 |
Why?
|
| Survival Rate | 1 | 2021 | 12541 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 1504 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 1569 | 0.020 |
Why?
|
| Titrimetry | 1 | 2005 | 11 | 0.020 |
Why?
|
| Vitronectin | 1 | 2005 | 24 | 0.020 |
Why?
|
| Fluoresceins | 1 | 2005 | 74 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 284 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 139 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2005 | 526 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 1028 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2453 | 0.010 |
Why?
|
| Brain | 1 | 2012 | 4208 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 39890 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 5595 | 0.000 |
Why?
|